• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
J Clin Invest. Dec 1993; 92(6): 2653–2659.
PMCID: PMC288462

Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men.

Abstract

Solute-free water diuretics (aquaretics) by antagonizing hydrosmotic vasopressin receptors (V2) may be useful in treating water-retaining diseases. The effects of intravenous administration of a newly developed nonpeptide, selective V2 antagonist, OPC-31260, at doses ranging from 0.017 to 1.0 mg/kg to groups of healthy, normally hydrated men were compared with those of 0.33 mg/kg furosemide and placebo. OPC-31260 increased the hypotonic urine volume dose dependently for the first 4 h, while furosemide induced sodium diuresis for 2 h. The absolute increase in the cumulative response in the urine to the highest doses of OPC-31260 was not significantly different from that to furosemide. The higher doses of OPC-31260 rapidly lowered urine osmolality for 2 h, particularly between minutes 15 and 45 (e.g., 1.0-mg/kg dose: 63 +/- 2 mOsm/kg in urine collected between minutes 30 and 45). In a marked hypotonic diuresis, mean free water clearance of the 4-h urine increased dose proportionally into the positive range, reaching 1.80 +/- 0.21 ml/min at 1.0 mg/kg. Whereas furosemide induced marked Na and K diuresis, OPC-31260 increased urinary Na excretion only slightly. At 4 h, 0.75 and 1.0 mg/kg of OPC-31260 almost doubled the plasma arginine vasopressin; and the higher doses increased plasma osmolality and plasma Na slightly, but did not alter plasma K, blood pressure, or heart rate. OPC-31260 thus safely induced a potent aquaretic effect in men.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.3M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Goldsmith SR, Francis GS, Cowley AW, Jr, Levine TB, Cohn JN. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol. 1983 Jun;1(6):1385–1390. [PubMed]
  • Szatalowicz VL, Arnold PE, Chaimovitz C, Bichet D, Berl T, Schrier RW. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med. 1981 Jul 30;305(5):263–266. [PubMed]
  • Bichet D, Szatalowicz V, Chaimovitz C, Schrier RW. Role of vasopressin in abnormal water excretion in cirrhotic patients. Ann Intern Med. 1982 Apr;96(4):413–417. [PubMed]
  • Brooks DP, Koster PF, Albrightson-Winslow CR, Stassen FL, Huffman WF, Kinter LB. SK&F 105494 is a potent antidiuretic hormone antagonist in the rhesus monkey (Macaca mulatta). J Pharmacol Exp Ther. 1988 Apr;245(1):211–215. [PubMed]
  • Hofbauer KG, Mah SC, Opperman JR. Chronic blockade of vasopressin receptors in rats. J Cardiovasc Pharmacol. 1986;8 (Suppl 7):S56–S60. [PubMed]
  • Kinter LB, Churchill S, Stassen FL, Moore M, Huffman W. Vasopressin antagonism in the squirrel monkey (Saimiri sciureus). J Pharmacol Exp Ther. 1987 Jun;241(3):797–803. [PubMed]
  • Stassen FL, Erickson RW, Huffman WF, Stefankiewicz J, Sulat L, Wiebelhaus VD. Molecular mechanisms of novel antidiuretic antagonists: analysis of the effects on vasopressin binding and adenylate cyclase activation in animal and human kidney. J Pharmacol Exp Ther. 1982 Oct;223(1):50–54. [PubMed]
  • Yamamura Y, Ogawa H, Yamashita H, Chihara T, Miyamoto H, Nakamura S, Onogawa T, Yamashita T, Hosokawa T, Mori T, et al. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol. 1992 Apr;105(4):787–791. [PMC free article] [PubMed]
  • Manning M, Przybylski JP, Olma A, Klis WA, Kruszynski M, Wo NC, Pelton GH, Sawyer WH. No requirements of cyclic conformation of antagonists in binding to vasopressin receptors. Nature. 329(6142):839–840. [PubMed]
  • Manning M, Sawyer WH. Discovery, development, and some uses of vasopressin and oxytocin antagonists. J Lab Clin Med. 1989 Dec;114(6):617–632. [PubMed]
  • Brooks DP, Koster PF, Albrightson CR, Huffman WF, Moore ML, Stassen FL, Schmidt DB, Kinter LB. Vasopressin receptor antagonism in rhesus monkey and man: stereochemical requirements. Eur J Pharmacol. 1989 Jan 24;160(1):159–162. [PubMed]
  • Huffman WF, Albrightson-Winslow C, Brickson B, Bryan HG, Caldwell N, Dytko G, Eggleston DS, Kinter LB, Moore ML, Newlander KA, et al. A minor modification of residue 1 in potent vasopressin antagonists dramatically reduces agonist activity. J Med Chem. 1989 Apr;32(4):880–884. [PubMed]
  • Thibonnier M. Vasopressin agonists and antagonists. Horm Res. 1990;34(3-4):124–128. [PubMed]
  • Yamamura Y, Ogawa H, Chihara T, Kondo K, Onogawa T, Nakamura S, Mori T, Tominaga M, Yabuuchi Y. OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist. Science. 1991 Apr 26;252(5005):572–574. [PubMed]
  • Ohnishi A, Ko Y, Fujihara H, Miyamoto G, Okada K, Odomi M. Pharmacokinetics, safety, and pharmacologic effects of OPC-21268, a nonpeptide orally active vasopressin V1 receptor antagonist, in humans. J Clin Pharmacol. 1993 Mar;33(3):230–238. [PubMed]
  • Albrightson-Winslow CR, Caldwell N, Brooks DP, Huffman WF, Stassen FL, Kinter LB. Cyclooxygenase inhibition unmasks the full antidiuretic agonist activity of the vasopressin antagonist, SK&F 101926, in dogs. J Pharmacol Exp Ther. 1989 May;249(2):366–371. [PubMed]
  • Robertson GL, Mahr EA, Athar S, Sinha T. Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma. J Clin Invest. 1973 Sep;52(9):2340–2352. [PMC free article] [PubMed]
  • Robertson GL, Shelton RL, Athar S. The osmoregulation of vasopressin. Kidney Int. 1976 Jul;10(1):25–37. [PubMed]
  • Sladek CD, Blair ML, Ramsay DJ. Further studies on the role of angiotensin in the osmotic control of vasopressin release by the organ-cultured rat hypothalamo-neurohypophyseal system. Endocrinology. 1982 Aug;111(2):599–607. [PubMed]
  • Padfield PL, Morton JJ. Effects of angiotensin II on arginine-vasopressin in physiological and pathological situations in man. J Endocrinol. 1977 Aug;74(2):251–259. [PubMed]
  • Reif MC, Troutman SL, Schafer JA. Sodium transport by rat cortical collecting tubule. Effects of vasopressin and desoxycorticosterone. J Clin Invest. 1986 Apr;77(4):1291–1298. [PMC free article] [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • Compound
    Compound
    PubChem Compound links
  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...